MEK114375: A Rollover Study to Provide Continued Treatment With GSK1120212 to Subjects With Solid Tumors and Leukemia
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2018
At a glance
- Drugs Trametinib (Primary) ; Carboplatin; Docetaxel; Erlotinib; Everolimus; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Leukaemia; Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis
- 19 Jul 2018 Status changed from active, no longer recruiting to completed.
- 19 Mar 2018 This trial has been completed in France according to European Clinical Trials Database record.
- 10 Jan 2018 Planned End Date changed from 30 Nov 2017 to 30 Aug 2018.